Wednesday, 18 Oct 2017

You are here

Curbside Consults - July 2017

Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines.

Case 1JU. Today I saw a new psoriatic arthritis patient who has recently had MRSA infections that included one hospitalization due to MRSA of a knee after cortisone injection knee.  The patient is on a DMARD but needs more aggressive therapy – more than bleach baths and prayer. Can she receive a biologic?

  • Answer:  it is very important to note that when it comes to serious infectious events (SIE), the general rule is that once you have an SIE, you are more likely to have a recurrence of it and that it may be more severe or fatal next time around. Hence, this patient is henceforth, at a greater risk to have either septic arthritis or a repeat MRSA infection.  This increased risk is not affected by the therapy you use (it will happen on MTX or on tocilizumab, etc.) unless you are also using high dose steroids or the patient has numerous SIE risk factors.  For patients such as this it may be instructive to use the RABBIT SIE Risk Calculator (here).  That said, there is no link or direct risk between MRSA and use of TNF inhibitors, other biologics or novel therapies.   I would use any or all necessary therapies once the MRSA infection is treated and/or controlled.  There is an interesting report from earlier this year showing that the types and factors underlying septic arthritis in rheumatoid arthritis (RA) has evolved from 1979-2013  with more cases of septic arthritis, more biologic use, more polyarticular infections, more MRSA (6% v 31%); but same age, sex, RF+, steroid use and outcomes; including death. (Citation source http://buff.ly/2u6OZTL)

Case 2JU.  I have a PsA patient who was successfully treated with Remicade for 6 years, and had to stop 7 months ago when he took BCG therapy for bladder cancer. Is there any literature or advice concerning when to restart Remicade for PsA after the patient has concluded BCG intravessicular therapy?  

  • Answer: Great question, but I am not sure there is a clear answer. Thus, we would welcome input from anyone who has already gone through this situation. My answer would have been guided by either a urologic guideline or the pharmacokinetic 1/2 life.  However, the 1/2 life is unknown and stopping rules on BCG related more to failure than success.  BCG is usually given as a 3 week or 6 week course and may be repeated.   Whether given as bladder installations or percutaneously, active BCG treatment should never be combined with TNF inhibitor therapy as there is a risk of TB infection.  Such risk would be far less if the patient were to receive other non-TNF drugs (e.g., ABA, TCZ, anakinra, RTX, Tofa).   I would probably wait a month after being off BCG before restarting Remicade. It may be better to use an alternative biologic and wait several months to see if the new agent works or if you need to return to infliximab therapy.  It’s unclear if there is a benefit (or lower risk) to waiting 2 months or more.

Case 3JU.   I sent a patient to get Zostavax and Prevnar-13.  Pharmacist gave her the Zostavax and told her she must wait a month before allowed to get the Prevnar-13.  Also, any update on release date of new shingles vaccine and whether there would be a waiting period if one had the Zostavax previously (like the year between a Pneumovax and Prevnar-13)?

  • Answer:  At issue here is whether you can give multiple vaccines at the same time and the answer is YES - you can give multiple vaccines together - the military does it all the time with their vaccine gun approach to mass immunization of the militia.  Moreover, the Prevnar PI says it can be given together with the flu vaccine (showed noninferiority - see below).  The CDC website on vaccines also says multiple vaccines are safe and commonly recommended in children.   The new shingles subunit will not be available until 2018 - it will be three shots and may have many constitutional side effects (e.g., myalgias, fever, etc.) and will be more expensive. Yes, it works better and thus may be worth the wait for some.  For now, I’m giving the current zoster vaccine to all those eligible and nearly all those going on a JAK inhibitor. 

Case 4JU. Can you remind me of what biologics you are comfortable using in patients with nonturberculous mycobacterial (NTM) infections (MAC or MAI)?

  • Answer:  There are many options for those patients who have MAC/MAI infections.  These include abatacept, tofacitinib, rituximab, and tocilizumab. If this occurred in a patients with PsA or SLE I would have no problem using belimumab, rituximab, secukinumab, ixekizumab, ustekinumab, apremilast or the newly approved guselkumab.  TNF is needed to form and maintain granulomas, thus anti-TNF therapies are risky in patients with NTM infections that cannot be completely eradicated.  Non-TNF therapies are much safer.  I would thusly avoid all TNF inhibitors, prednisone and leflunomide. The leflunomide package insert requires PPD testing and has been associated with mycobacterial infections. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

How about IV cyclophosphamide with atypical AFB in bronch wash(may be colonization) in patient on steroids with severe fulminant CTD related ILD who has failed azathioprine and cellcept?
I couldnt possibly answer this as presented. Youre talking about the most toxic drug in a refractory difficult to treat disease with an opportunistic infection that cannot be cured. Sorry. Such requires a hour long conference with multiple specialists.
Assuming that active and severe psoriasis is not the potential cause of the Staph sepsis, I would favor a non-TNF agent or apremilast AFTER checking complement levels and Ig levels for possible immunodeficiency.
I would like to add a question to the next "Curbside"? 45 yo Woman with RA. Currently on Enbrel and Plaquenil. Dose appropriate plaquenil. Attempted to discontinue with the onset of tinnitus - but she worsens off of it.The question revolves around an MRI brain performed where lesions suggestive for demyelination were returned (Neurology rules out MS). The tinnitus not related to the lesions. So, the question, in a woman doing well on Enbrel would these asymptomatic lesions be reason to stop the Enbrel?

More Like This

Novel Gel Drug Delivery Developed for Rheumatoid Arthritis

Scientists at the Institute for Basic Science have invented a hydrogel capable of delivering drug at sites of inflammation in disorders such as rheumatoid arthritis. Published in Advanced Materials, this jelly-like material could be used to absorb extra fluids in swelling joints and release drugs wherever nitric oxide is produced in abundance.

2016 EULAR Guidelines on RA Management

The management of rheumatoid arthritis (RA) has evolved significantly with time.  Nevertheless, there are still some uncertainties - such as when, what and which biologic or novel therapy should be used.

New EULAR Guidelines for Ultrasound Use

In the current issue of ARD, the European League Against Rheumatism (EULAR) has revised and updated its 2001 guideline for musculoskeletal (MS) ultrasound (US) in rheumatology; this time incorporating new advances, technological developments and use indications in rheumatology. EULAR has provided this as an educational tool and standard reference for MSUS practice and research in rheumatology.

The Unregulated $37 Billion Supplement Industry

In 1994 there were 600 supplement companies, producing 4,000 OTC supplement products for a total revenue of about $4 billion. Today we have close to 6,000 companies, producting nearly 75,000 supplement products, bringing in $37 billion annually.  And all of this is regulated by 26 people and a budget of $5 million at the FDA.

Drug Costs Vary by 600% in Different Countries

The Canadian Medical Association Journal has studied the costs of prescription drugs in 10 high-income countries (seven European countries, Australia, Canada and New Zealand) and found that many of these medicines varied by more than 600%.